Article

Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity

University of Cambridge, Cambridge, England, United Kingdom
Nature Genetics (Impact Factor: 29.65). 04/2007; 39(3):329-37. DOI: 10.1038/ng1958
Source: PubMed

ABSTRACT Autoimmune diseases are thought to result from imbalances in normal immune physiology and regulation. Here, we show that autoimmune disease susceptibility and resistance alleles on mouse chromosome 3 (Idd3) correlate with differential expression of the key immunoregulatory cytokine interleukin-2 (IL-2). In order to test directly that an approximately twofold reduction in IL-2 underpins the Idd3-linked destabilization of immune homeostasis, we show that engineered haplodeficiency of Il2 gene expression not only reduces T cell IL-2 production by twofold but also mimics the autoimmune dysregulatory effects of the naturally occurring susceptibility alleles of Il2. Reduced IL-2 production achieved by either genetic mechanism correlates with reduced function of CD4(+) CD25(+) regulatory T cells, which are critical for maintaining immune homeostasis.

0 Followers
 · 
110 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetic variants in il2 and il2ra have been associated with autoimmune disease susceptibility in both genome-wide association studies (GWAS) in humans and in genetic linkage studies in experimental models of autoimmunity. Specifically, genetic variants resulting in a low IL-2 phenotype are susceptibility alleles while variants resulting in a high IL-2 phenotype are resistance alleles. The association of high IL-2 phenotypes with resistance has been attributed primarily to the T cell intrinsic promotion of regulatory T cell development, maintenance, and function; however, IL-2 can also act T cell intrinsically to dampen differentiation of pathogenic IL-17-producing Th17 cells. Here, we have uncovered a novel T cell extrinsic mechanism whereby IL-2 promotes both IFN-γ and IL-27 production from tissue resident macrophages which in turn dampen the differentiation of pathogenic Th17 cells. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Journal of Autoimmunity 02/2015; 59. DOI:10.1016/j.jaut.2015.02.001 · 7.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-dose IL-2 administration suppresses unwanted immune responses in mice and humans, thus evidencing the potential of IL-2 to treat autoimmune disorders. Increased Tregs activity is one of the potential mechanisms by which low-dose IL-2 immunotherapy induces immunosuppression. In addition, recent data indicate that IL-2 may contribute to prevent unwanted self-reactive responses by preventing the developing of T-follicular helper cells, a CD4(+) T-cell subset that expands in autoimmune disease patients and promotes long-term effector B-cell responses. Here we discuss the mechanisms underlying the clinical benefits of low-dose IL-2 administration, focusing on the role of this cytokine in promoting Treg-mediated suppression and preventing self-reactive T-follicular helper cell responses.
    Immunotherapy 11/2014; 6(11):1207-20. DOI:10.2217/imt.14.83 · 2.44 Impact Factor
  • Frontiers in Bioscience 01/2008; Volume(13):4838. DOI:10.2741/3043 · 4.25 Impact Factor

Full-text (2 Sources)

Download
61 Downloads
Available from
May 19, 2014